Overall outcome of peptide receptor radionuclide therapy (PRRT) in treatment metastatic progressive neuroendocrine tumors (NETs): Survival, toxicity and prognostic factors

#3208

Introduction: NETs are a group of malignancies that frequently express somatostatin receptors which allow treatment with PRRT.

Aim(s): To evaluate the efficacy and toxicity of PRRT and to assess the impact of some factors on the outcome.

Materials and methods: A retrospective analysis of 394 patients (170 female, 194 male, mean age 61.83 ± 5) with metastatic progressive NETs who were treated PRRT. The average administered activity was 7.477 GBq (SD +/- 0.02) per cycle with standard intervals of 10-12 weeks. Therapy response assessed using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1). Analysis of progression-free survival (PFS) and overall survival (OS) was estimated using Kaplan-Meier; hazard ratios (HRs) with 95% CIs were estimated using Cox Regression. Toxicity was defined using Common Terminology Criteria for Adverse Events version 5 (CTCAE 5.0).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Alsadik S, Gnanasegaran G, Chen L, Toumpanakis C, Caplin M,

Keywords: neuroendocrine tumor, NET, peptide receptor radionuclide therapy PRRT,